Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.200-1.346 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of $52.1 billion-$54.5 billion, compared to the consensus revenue estimate of $52.1 billion.

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS:BAYRY traded up $0.23 on Wednesday, hitting $14.21. 438,235 shares of the company were exchanged, compared to its average volume of 1,245,646. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The stock’s 50 day moving average price is $12.43 and its 200 day moving average price is $12.09. The firm has a market capitalization of $55.85 billion, a P/E ratio of -22.20, a price-to-earnings-growth ratio of 4.35 and a beta of 0.55. Bayer Aktiengesellschaft has a 1-year low of $7.19 and a 1-year high of $15.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. The company had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Sell-side analysts predict that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

Wall Street Analyst Weigh In

BAYRY has been the subject of a number of analyst reports. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Finally, Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Bayer Aktiengesellschaft has an average rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.